Orgenesis, Inc.

0.9100+0.76 (+507%)

Oct 30, 10:03:03 AM EDT · OTC Markets EXMKT · ORGS · USD

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

4.71M

P/E (TTM)

Basic EPS (TTM)

-24.46

Dividend Yield

Recent Filings

8-K

Theracell secures $1M loan

9/16/25Sep 16, 2025

Orgenesis subsidiary Theracell inked a $1M convertible loan with Alpha Prosperity Fund on September 10, 2025, at 10% interest over 36 months, plus access to a $10M facility—$7.1M already drawn, wiping out prior $6.1M debts. The lender snags warrants for 15% equity at $250K exercise and potential board seats for three members after 30 days. Lender eyes up to 80% control via conversion, but shareholder nod required. Yet dilution looms large.

8-K

Director Ashish Nanda resigns

8/25/25Aug 25, 2025

Orgenesis Inc. announced the immediate resignation of director Ashish Nanda on August 21, 2025, effective that day. The move stemmed from no disagreements with management or operations. Nanda's departure leaves the board leaner. Yet the company expressed thanks for his past input.

8-K

Key resignations at Orgenesis

8/19/25Aug 19, 2025

Orgenesis Inc. saw its CFO Victor Miller resign on August 8, 2025, to pursue other opportunities, with no disagreements cited. Directors Yaron Adler and Adam Pelavin followed suit on August 9, while Santhosh Nagaraja stepped down on August 18, all without conflicts over operations or policies. These abrupt exits signal potential leadership flux. The company expressed thanks for their contributions.

8-K

Orgenesis stock delisted to Expert Market

8/1/25Aug 1, 2025

Orgenesis Inc. faces a sharp setback as OTC Markets shifts its common stock from Pink Limited to the Expert Market tier, effective immediately after a July 29, 2025 notification. The move stems from over 180 days of delinquency in filing its 2024 10-K, breaching SEC Rule 15c2-11 despite a failed 15-day cure attempt. This delisting curtails broker-dealer quoting, squeezing liquidity for investors. Compliance lags hit hard.

8-K

Orgenesis delisted to Pink tier

6/6/25Jun 6, 2025

Orgenesis Inc. faces a setback as OTC Markets shifts its common stock from the OTCQX to the Pink Limited tier, effective June 3, 2025, due to failure to file the 2024 10-K within the cure period. This delisting stems from ongoing reporting delinquencies first flagged on April 17, 2025. The move signals heightened scrutiny on compliance. Investors should watch for filing updates.

About

Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. It also provides hospital services and cell process development services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

CEO

Ms. Vered Caplan M.Sc.

IPO

3/13/2012

Website

https://orgenesis.com

Employees

146

Sector

Healthcare

Industry

Biotechnology